The Company’s advanced portfolio targets large and important markets with significant unmet clinical needs, including i) Lynovex Oral and Lynovex Inhaled, two orphan drug candidates for cystic fibrosis (CF), ii) Novexatin, a potential step change therapy for onychomycosis, out-licensed to Taro Pharmaceuticals, and iii) its proprietary antimicrobial peptide rational drug design platform, that has generated Novamycin, a novel first-in-class antifungal, as well as Novexatin.
Lead clinical products
NP213 (Novexatin®) Phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis) being co-developed with the Company’s global licensing partner, Taro Pharmaceuticals.
NM001 (Lynovex®) A unique dual antibacterial-mucolytic orphan drug candidate in late stage clinical evaluation for cystic fibrosis.
Pipeline and Partnering
NovaBiotics is developing its robust pipeline of antibacterial and antifungal candidates for medically unmet conditions with significant market potential to early/mid clinical proof of concept, before out-licensing or securing co-development partnerships.